What Happens When You Stop Wegovy: The Decision Explained

Weight regain after stopping semaglutide is well-documented in clinical evidence, not an edge case — the STEP 1 trial extension found participants regained roughly two-thirds of lost weight within a year of stopping.
Appetite and gastric-emptying effects reverse as the medicine clears your system, typically over a few weeks after the final dose.
Any weight-related health conditions that improved during treatment (blood pressure, blood sugar, cholesterol) can begin to return toward baseline as weight goes back on.
Stopping is sometimes planned and appropriate; the right approach depends on your reasons, your health status, and what ongoing support is in place.

When you stop Wegovy, appetite typically returns to its pre-treatment level within days to weeks, and most people gradually regain a significant portion of the weight they lost. Clinical trials show that much of this regain happens within a year of stopping, because semaglutide was suppressing hunger signals that don't disappear permanently. These are prescription-only medicines, and any decision about stopping should be made with the prescriber who knows your full picture.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Thinking Through the Decision to Stop Wegovy

Why stopping feels manageable at first — but changes over the following months

The effects of semaglutide on appetite don't vanish the moment you put the pen down. Wegovy has a half-life of roughly one week, so it clears gradually. For the first few weeks after your final dose you may notice hunger creeping back incrementally rather than all at once. That slow return can feel deceptively fine.

The harder part comes later. Data from the STEP 1 trial extension (published in the New England Journal of Medicine and covering 68 weeks on treatment then a further year off it) showed participants regained around 6.9 percentage points of body weight within a year of stopping, recovering roughly two-thirds of what they had lost. For someone who had lost 15 kilograms, that is a meaningful reversal. The STEP 1 trial paper in the NEJM is the clearest source on what actually happens in the period after the medicine stops.

This isn't a failure on the patient's part. Obesity has a strong biological component: the hormonal and neurological signals that drive hunger don't reset permanently during treatment. When the external signal from semaglutide is removed, the underlying biology reasserts itself. If you want to understand what actually happens if you stop Wegovy, from appetite changes through to weight regain, it is worth reading through that before making any decision. The practical timeline matters too. If you're stopping around a holiday, a period of work stress, or a point where your routines are already disrupted, you may want to discuss the timing with your prescriber rather than simply letting the prescription lapse.

The health conditions that improved may not stay improved

For many people, the benefit of Wegovy isn't just the number on the scale. Blood pressure often falls during treatment. Blood sugar and cholesterol profiles improve. Sleep apnoea can become less severe. These changes are largely weight-dependent: as weight returns, those markers tend to follow.

The NHS guidance on weight management injections is clear that these medicines work best alongside sustained dietary and physical-activity changes, precisely because those lifestyle factors give you something to stand on once the medicine stops. If those habits are in place, the reversal can be slower and less complete. If they aren't, the evidence suggests the return to baseline is faster.

This is part of why a good prescriber will want to understand why you are stopping. Side effects that aren't resolving, a planned pregnancy (Wegovy is not recommended in pregnancy or while trying to conceive), changes in health status, or a clinical review decision are all legitimate and different situations. Each changes what stopping looks like and what follow-up is sensible. The same goes for people who have been on treatment for some time and wonder what the longer-term picture after stopping Wegovy actually looks like.

When stopping is the right decision, and what to do differently this time

Stopping isn't inherently wrong. NICE's recommendation for semaglutide under TA875 includes a maximum treatment duration of two years within specialist NHS services, which reflects the reality that these are not lifelong licences in every context. Private treatment has no equivalent fixed cap, but most prescribers will want a clinical reason to continue at each review as well as a clinical reason to stop.

If you're considering stopping, the most useful things to have in place are: a realistic picture of what your weight and appetite are likely to do when you stop taking Wegovy, a diet and activity plan that isn't dependent on pharmaceutical appetite suppression, and a follow-up pathway so you're not just left waiting to see what happens. Some people restart treatment after a break if regain is clinically significant. Others transition to a different approach. You can read more about the treatment options available through a private regulated route on the weight management overview.

If your reason for stopping is cost, it is worth being honest with your prescriber about that rather than simply not reordering. A clear explanation of what Wegovy costs privately and what that includes can help you weigh the options, and a prescriber can sometimes discuss whether a dose or schedule change is clinically appropriate.

If you have questions about how the medicine works while you are on it, a plain-language explanation of what Wegovy does during treatment can put the stopping question in context. Our guidance on what happens when you stop using Wegovy covers the practical side of that transition in more detail. And if you're curious whether a different injectable medicine might suit your situation better, our prescribers can discuss that as part of a consultation. Start your free consultation and a GPhC-registered prescriber will review your circumstances the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions